Who is sponsoring NCT02132845?

NCT02132845 is sponsored by Fox Chase Cancer Center.

What drugs are being tested in NCT02132845?

Interventions in NCT02132845: cytology specimen collection procedure, targeted therapy, therapeutic procedure, laboratory biomarker analysis.

What condition does NCT02132845 study?

NCT02132845 studies Malignant Neoplasm.

Is NCT02132845 still recruiting?

NCT02132845 is currently completed. Last updated 4 February 2021.

Last reviewed 2021-02-04 · How we verify

NCT02132845

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Next Generation Sequence Target-Directed Therapy in Treating Patients With Cancer

Completed NA Last updated 4 February 2021

What this trial tests

NA trial testing cytology specimen collection procedure in Malignant Neoplasm in 30 participants. Completed in 10 May 2018.

Timeline

17 March 2016

Primary endpoint
10 May 2018

10 May 2018

Quick facts

Lead sponsor	Fox Chase Cancer Center
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	30
Start date	17 March 2016
Primary completion	10 May 2018
Estimated completion	10 May 2018
Sites	1 location across United States

Drugs / interventions tested

cytology specimen collection procedure
targeted therapy — full drug profile →
therapeutic procedure
laboratory biomarker analysis — full drug profile →

Conditions studied

Malignant Neoplasm — all drugs for Malignant Neoplasm →

Sponsor

Fox Chase Cancer Center — full company profile →

Who can join

19 and older, any sex, with Malignant Neoplasm. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This randomized clinical trial studies how well next generation sequence target-directed therapy works in treating patients with cancer. Next generation sequencing is a test that screens for mutations to cancer related genes. Target-directed therapy is a type of treatment that uses drugs or other substances to identify and attack specific types of cancer cells that may have less harm to normal cells. Next generation sequencing may help identify these specific types of cancer cells.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Next-generation sequencing for guiding matched targeted therapies in people with relapsed or metastatic cancer.
Kazmi F, Shrestha N, Liu TFD, Foord T, et al · · 2025 · cited 5× · PMID 40122129 · DOI 10.1002/14651858.cd014872.pub2

Verify or expand the search:

Other trials of cytology specimen collection procedure

Trials testing the same drug.

NCT02280161 — Germ-Line Mutations in Blood and Saliva Samples From Patients With Cancer · recruiting
NCT02250404 — Molecular Signatures of Relapse in Tissue Samples From Patients With Small Cell Lung Cancer Who Are Receiving Cisplatin · withdrawn
NCT02273336 — Comprehensive Genomic Analysis in Tissue and Blood Samples From Young Patients With Lung Cancer · completed
NCT02250352 — Core Biopsies for Establishing a Breast Tumor Tissue Repository · recruiting
NCT01987726 — Comprehensive Gene Sequencing in Guiding Treatment Recommendations Patients With Metastatic or Recurrent Solid Tumors · completed

Other recruiting trials for Malignant Neoplasm

Currently open trials in the same condition.

NCT07302347 — A Study of Pembrolizumab in Japanese Pediatric Participants With Solid Tumors or Lymphomas and Japanese Adult Participan · Phase 1, PHASE2 · recruiting
NCT07487883 — Cadherin 3(CDH3)-Targeted PET in Lung Malignant Tumors · recruiting
NCT07252739 — KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) · Phase 2 · recruiting
NCT07247110 — A Clinical Study of MK-4716 in People With Certain Solid Tumors (MK-4716-001) · Phase 1 · recruiting
NCT07131007 — Construction and Evaluation of Tumor Immunotherapy and Organ Damage Early Warning System Based on Multi-omics · recruiting

Other Fox Chase Cancer Center trials

Trials by the same sponsor.

NCT07455032 — Neoadjuvant CADI-05 in Combination With Pembrolizumab for Surgically Resectable Locally Advanced Head and Neck Squamous · Phase 1 · recruiting
NCT07221942 — Pembrolizumab Maintenance After Enfortumab Vedotin (EV)/Pembro Induction in Front-Line Metastatic Urothelial Carcinoma · Phase 2 · recruiting
NCT07221058 — Adaptive Radiation Boost for Rectal Cancer · Phase 1 · recruiting
NCT07167446 — Neuroprotective Potential of Cannabidiol (CBD) in Preventing Oxaliplatin (Ox)-Induced Neuropathy · EARLY_PHASE1 · recruiting
NCT07219303 — Adaptive Radiation Therapy for Men With Intermediate- or High-Risk Prostate Cancer · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02132845 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Fox Chase Cancer Center
Last refreshed: 4 February 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02132845.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing